Hims & Hers Scales Subscribers and International Revenue, but Margin Compression and Negative Free Cash Flow Test the Growth Story

What happened

Hims & Hers reported Q2 2026 revenue of $753.2 million, up 38% year over year, with subscribers reaching nearly 3 million and monthly revenue per subscriber rising to $92, as the company's branded GLP-1 pivot and international expansion drove reacceleration. International revenue reached $131 million, and testosterone is approaching the company's sixth U.S. specialty with an annual run rate above $100 million, indicating broadening beyond weight loss. However, gross margin fell sharply to 64% from 76% a year earlier, driven by higher costs from the weight-loss mix shift, and the company posted a net loss of $86.3 million. Free cash flow turned negative at -$68 million for the quarter, reflecting increased investment and working capital needs, while total liabilities climbed to $3.3 billion including convertibles and deferred acquisition payables. The July 2026 FTC lawsuit over privacy and billing practices adds regulatory risk to a model that still relies heavily on direct-response customer acquisition.

Implication

Investors should focus on whether Q3 2026 sustains the demand rebound while keeping gross margin at or above 64%, as another quarter of margin compression would undermine the margin-repair thesis. The negative free cash flow, if it persists, raises concerns about balance sheet strain given $1.365 billion in convertibles and over $703 million in deferred acquisition payables, potentially forcing dilution or curtailing growth investment. The FTC case remains a key risk; any mandated changes to subscription, billing, or advertising practices could increase customer acquisition costs and churn, directly hitting the growth engine. International expansion and new specialties like testosterone offer diversification, but they also require significant upfront investment, and their profitability has yet to be proven at scale. With the stock trading around $27 against a base case value of $29 and a bear case of $20, risk/reward remains unattractive; we maintain a WAIT rating and would only add on meaningful price weakness or clear evidence of margin stabilization.

Thesis delta

No change to the overall thesis: Hims remains a scaled self-pay telehealth platform with real branded GLP-1 access, but the transition has destroyed short-term profitability. The new details on testosterone and international revenue reinforce the diversification story, but they do not address the core issue of margin compression and negative free cash flow. Therefore, the WAIT rating stands, with heightened emphasis on cash flow sustainability as the next critical test.